Latest & greatest articles for acyclovir

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on acyclovir or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on acyclovir and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for acyclovir

41. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group.

Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. 7907729 1994 04 21 1994 04 21 2015 06 16 0140-6736 343 8900 1994 Mar 26 Lancet (London, England) Lancet Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. 749-53 Cytomegalovirus (CMV) infection is a major cause (...) of morbidity and mortality after allogeneic bone marrow transplantation (BMT). Our aim was to study the prophylactic effect of high-dose intravenous acyclovir given around the time of BMT followed by oral acyclovir on CMV infection and survival. 310 BMT recipients at risk of developing CMV infection were randomised to one of three regimens in a double-blind and double-dummy design: intravenous acylclovir (500 mg/m2, three times a day) for 1 month followed by oral acyclovir (800 mg four times a day

Lancet1994

42. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster.

A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. 8114860 1994 03 31 1994 03 31 2013 11 21 0028-4793 330 13 1994 Mar 31 The New England journal of medicine N. Engl. J. Med. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. 896-900 Acyclovir given for 7 to 10 days is of proved benefit in acute herpes zoster, but studies of its effectiveness in preventing (...) postherpetic neuralgia have had conflicting results. The role of corticosteroids in the treatment of herpes zoster is also controversial. We conducted a double-blind, controlled trial in patients with acute herpes zoster to determine whether either 21 days of acyclovir therapy or the addition of prednisolone offered any improvement over 7 days of acyclovir therapy. Patients with a rash of less than 72 hours' duration were assigned to receive acyclovir (800 mg orally, five times daily) for 7 days

NEJM1994

43. A controlled trial of acyclovir for chickenpox in normal children.

A controlled trial of acyclovir for chickenpox in normal children. 1944438 1991 12 04 1991 12 04 2013 11 21 0028-4793 325 22 1991 Nov 28 The New England journal of medicine N. Engl. J. Med. A controlled trial of acyclovir for chickenpox in normal children. 1539-44 Chickenpox, the primary infection caused by the varicella-zoster virus, affects more than 3 million children a year in the United States. Although usually self-limited, chickenpox can cause prolonged discomfort and is associated (...) with infrequent but serious complications. To evaluate the effectiveness of acyclovir for the treatment of chickenpox, we conducted a multicenter, double-blind, placebo-controlled study involving 815 healthy children 2 to 12 years old who contracted chickenpox. Treatment with acyclovir was begun within the first 24 hours of rash and was administered by the oral route in a dose of 20 mg per kilogram of body weight four times daily for five days. The children treated with acyclovir had fewer varicella lesions

NEJM1991

44. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.

A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. 1649971 1991 08 26 1991 08 26 2013 11 21 0028-4793 325 8 1991 Aug 22 The New England journal of medicine N. Engl. J. Med. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. 551-5 Most (...) strains of herpes simplex virus that are resistant to acyclovir are susceptible in vitro to both foscarnet and vidarabine. We conducted a randomized trial to compare foscarnet with vidarabine in 14 patients with the acquired immunodeficiency syndrome (AIDS) and mucocutaneous herpetic lesions that had been unresponsive to intravenous therapy with acyclovir for a minimum of 10 days. The patients were randomly assigned to receive either foscarnet (40 mg per kilogram of body weight intravenously every 8

NEJM1991

45. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group.

A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group. 1988829 1991 02 27 1991 02 27 2013 11 21 0028-4793 324 7 1991 Feb 14 The New England journal of medicine N. Engl. J. Med. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group. 444-9 Despite the use of vidarabine, herpes simplex virus (HSV (...) ) infection in neonates continues to be a disease of high morbidity and mortality. We undertook a controlled trial comparing vidarabine with acyclovir for the treatment of neonatal HSV infection. Babies less than one month of age with virologically confirmed HSV infection were randomly and blindly assigned to receive either intravenous vidarabine (30 mg per kilogram of body weight per day; n = 95) or acyclovir (30 mg per kilogram per day; n = 107) for 10 days. Actuarial rates of mortality and morbidity

NEJM1991

46. Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection. The Acyclovir Study Group.

Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection. The Acyclovir Study Group. 1990191 1991 03 01 1991 03 01 2016 10 17 0098-7484 265 6 1991 Feb 13 JAMA JAMA Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection. The Acyclovir Study Group. 747-51 In this 3-year study of suppressive acyclovir for recurrent genital herpes, patients with more than six (...) recurrences per year were randomized initially to 400 mg of acyclovir or placebo orally two times per day, with recurrences treated with 200 mg of acyclovir five times per day for 5 days. In the second year of the study, all patients received acyclovir as a daily suppressive or intermittent acute therapy; in the third year, all received daily acyclovir. Among 525 patients completing 3 study years, 289 received 3 years of suppressive therapy and 236 received 1 year of acute therapy followed by 2 years

JAMA1991

47. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts.

A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. 2541335 1989 06 16 1989 06 16 2013 11 21 0028-4793 320 21 1989 May 25 The New England journal of medicine N. Engl. J. Med. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. 1381-7 Cytomegalovirus is a major viral pathogen in patients who undergo renal transplantation, and (...) cytomegalovirus disease is difficult to treat. We therefore conducted a randomized, placebo-controlled, double-blind trial of acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts from cadavers. Acyclovir was given orally in doses of 800 to 3200 mg per day, according to the patients' estimated level of renal function. Patients took the first dose of either acyclovir or placebo six hours before transplantation and continued to take the assigned medication for 12 weeks

NEJM1989

48. Oral acyclovir for treatment of first-episode herpes simplex virus proctitis.

Oral acyclovir for treatment of first-episode herpes simplex virus proctitis. 3367455 1988 06 10 1988 06 10 2016 10 17 0098-7484 259 19 1988 May 20 JAMA JAMA Oral acyclovir for treatment of first-episode herpes simplex virus proctitis. 2879-81 Twenty-nine patients with first-episode rectal herpes simplex virus infection were enrolled in a double-blind trial of oral acyclovir, 400 mg five times daily, vs placebo treatment. Eighty percent of those receiving acyclovir compared with 25% of placebo (...) recipients no longer had herpes simplex virus isolated from their rectal lesions three days after onset of therapy. The median duration of rectal lesions and viral excretion from rectal lesions (median, five and zero days, respectively) was significantly shorter in patients treated with acyclovir than in placebo-treated patients (14 and 11 days, respectively). Durations of local signs and symptoms of proctitis, such as rectal pain, discharge, and friability, were shorter in acyclovir recipients than

JAMA1988

49. Acyclovir treatment of the chronic fatigue syndrome. Lack of efficacy in a placebo-controlled trial.

Acyclovir treatment of the chronic fatigue syndrome. Lack of efficacy in a placebo-controlled trial. 2849717 1989 01 30 1989 01 30 2013 11 21 0028-4793 319 26 1988 Dec 29 The New England journal of medicine N. Engl. J. Med. Acyclovir treatment of the chronic fatigue syndrome. Lack of efficacy in a placebo-controlled trial. 1692-8 Twenty-seven adults with a diagnosis of the chronic fatigue syndrome were enrolled in a double-blind, placebo-controlled study of acyclovir therapy. The patients had (...) had debilitating fatigue for an average of 6.8 years, accompanied by persisting antibodies to Epstein-Barr virus early antigens (titers greater than or equal to 1:40) or undetectable levels of antibodies to Epstein-Barr virus nuclear antigens (titers less than 1:2) or both. Each course of treatment consisted of intravenous placebo or acyclovir (500 mg per square meter of body-surface area) administered every eight hours for seven days. The same drug was then given orally for 30 days (acyclovir

NEJM1988

50. Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial.

Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial. 3290517 1988 07 29 1988 07 29 2016 10 17 0098-7484 260 2 1988 Jul 08 JAMA JAMA Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial. 201-6 Normal adults with six or more episodes of genital herpes in the previous year were enrolled in a one-year, multicenter, double-blind trial comparing (...) placebo with 400 mg of acyclovir administered orally twice daily. Patients with episodes during the study were offered 200 mg of acyclovir administered orally five times daily for five days; this allowed comparison of suppressive and episodic treatment. After one year, 227 (44%) of 519 patients receiving suppressive treatment and seven (2%) of 431 receiving placebo (episodic) treatment remained free of recurrences, and the mean numbers of recurrences per year were 1.8 and 11.4, respectively. Among 67

JAMA1988

51. Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes.

Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes. 2895840 1988 05 26 1988 05 26 2015 06 16 0140-6736 1 8591 1988 Apr 23 Lancet (London, England) Lancet Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes. 926-8 131 patients with frequently recurring genital herpes were treated for 1 year with reducing doses of oral acyclovir. The time to first recurrence in patients who commenced therapy on 400 mg twice a day (...) of recurrences (0.71 per 28 days) was significantly less than the pre-treatment period (p = 0.001). No important side-effects were seen. It is concluded that long-term suppression with acyclovir is safe and effective for patients with recurrent genital herpes. Mindel A A Academic Department of Genitourinary Medicine, University College, London. Faherty A A Carney O O Patou G G Freris M M Williams P P eng Clinical Trial Journal Article Randomized Controlled Trial England Lancet 2985213R 0140-6736 0 Tablets

Lancet1988

52. Treatment of first-attack genital herpes--acyclovir versus inosine pranobex.

Treatment of first-attack genital herpes--acyclovir versus inosine pranobex. 2437417 1987 06 24 1987 06 24 2015 06 16 0140-6736 1 8543 1987 May 23 Lancet (London, England) Lancet Treatment of first-attack genital herpes--acyclovir versus inosine pranobex. 1171-3 77 patients with a first attack of genital herpes were entered into a double-blind trial to compare the efficacy of acyclovir with that of inosine pranobex. 24 patients received acyclovir with that of inosine pranobex, and 28 both drugs (...) . Patients treated with acyclovir or both drugs healed more quickly and had a shorter duration of viral shedding than those treated with inosine pranobex. The time to first recurrence and frequency of subsequent recurrences were similar in the three treatment groups. Acyclovir is the treatment of choice for patients with a first attack of genital herpes. Mindel A A Kinghorn G G Allason-Jones E E Woolley P P Barton I I Faherty A A Jeavons M M Williams P P Patou G G eng Clinical Trial Comparative Study

Lancet1987

53. Vidarabine versus acyclovir therapy in herpes simplex encephalitis.

Vidarabine versus acyclovir therapy in herpes simplex encephalitis. 3001520 1986 02 06 1986 02 06 2013 11 21 0028-4793 314 3 1986 Jan 16 The New England journal of medicine N. Engl. J. Med. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. 144-9 We randomly assigned 208 patients who underwent brain biopsy for presumptive herpes simplex encephalitis to receive either vidarabine (15 mg per kilogram of body weight per day) or acyclovir (30 mg per kilogram per day) for 10 days (...) . Sixty-nine patients (33 percent) had biopsy-proved disease; 37 received vidarabine, and 32 acyclovir. The mortality in the vidarabine recipients was 54 percent, as compared with 28 percent in the acyclovir recipients (P = 0.008). Six-month mortality varied according to the Glasgow coma score at the onset of therapy. For scores of greater than 10, 7 to 10, and less than or equal to 6, mortality was 42, 46, and 67 percent in the patients treated with vidarabine, as compared with 0, 25, and 25 percent

NEJM1986

54. Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine.

Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine. 3001523 1986 02 11 1986 02 11 2016 04 22 0028-4793 314 4 1986 Jan 23 The New England journal of medicine N. Engl. J. Med. Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine. 208-12 In a prospective, randomized trial, we compared intravenous acyclovir and vidarabine (...) in the treatment of varicella-zoster virus infection in severely immunocompromised patients who presented within 72 hours of onset of the infection. Eleven patients were treated in each group. Cutaneous dissemination of infection occurred in none of the 10 acyclovir recipients and in 5 of the 10 vidarabine recipients who had presented with localized dermatomal disease (P = 0.016). As compared with vidarabine, acyclovir treatment shortened the median periods during which cultures were positive for the virus

NEJM1986

55. Prevention of herpesvirus infections in renal allograft recipients by low-dose oral acyclovir.

Prevention of herpesvirus infections in renal allograft recipients by low-dose oral acyclovir. 2999455 1986 01 15 1986 01 15 2016 10 17 0098-7484 254 24 1985 Dec 27 JAMA JAMA Prevention of herpesvirus infections in renal allograft recipients by low-dose oral acyclovir. 3435-8 Forty patients with serum antibody against herpes simplex virus (HSV) were enrolled in a randomized, placebo-controlled, double-blind investigation of acyclovir given orally in a low dosage as prophylaxis against recurrent (...) HSV infection after renal transplantation. During 30 postoperative days of medication, 14 of 21 placebo-treated and one of 19 acyclovir-treated patient(s) developed reactivation of HSV infection. Eleven of the former, but not the latter, had herpetic lesions. The protection against active infection with HSV during the period of prophylaxis with acyclovir is statistically highly significant. From 30 to 90 days after transplantation when no antiviral medicine was given, 60% (3/5) of the remaining

JAMA1985

56. Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial.

Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. 6368877 1984 05 10 1984 05 10 2016 10 17 0098-7484 251 16 1984 Apr 27 JAMA JAMA Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. 2103-7 Two hundred fifty patients were entered into a multicenter trial to evaluate the efficacy and toxicity of orally administered acyclovir for treatment of recurrent genital herpes. The study consisted of part (...) A, in which patients entered the study within 48 hours of the onset of lesions, and part B, in which patients self-initiated therapy as soon as possible after the onset of a recurrent episode. In both parts, patients received either acyclovir (200 mg) or placebo, five times daily for five days. In both parts, the duration of virus shedding and the time to crusting and healing of lesions were shorter among acyclovir recipients than among placebo recipients. In part B, fewer acyclovir recipients formed new

JAMA1984

57. Prophylactic oral acyclovir in recurrent genital herpes.

Prophylactic oral acyclovir in recurrent genital herpes. 6146006 1984 08 20 1984 08 20 2015 06 16 0140-6736 2 8394 1984 Jul 14 Lancet (London, England) Lancet Prophylactic oral acyclovir in recurrent genital herpes. 57-9 56 patients with frequently recurring genital herpes were treated in a randomised double-blind trial with either oral acyclovir 200 mg four times a day or placebo for 12 weeks. 29 patients received the drug and 27 the placebo. The mean recurrence rate per month of treatment (...) was 1.4 in the placebo-treated patients and 0.05 in the acyclovir group. Median time to the first recurrence after the start of therapy was 14 days in the placebo group compared with 100 days in the acyclovir group. After the end of treatment the recurrence rate was similar in the two groups. Prophylactic oral acyclovir seems to be an effective treatment for patients with frequently recurring genital herpes. Mindel A A Weller I V IV Faherty A A Sutherland S S Hindley D D Fiddian A P AP Adler M W MW

Lancet1984

58. Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients.

Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients. 6148470 1984 11 01 1984 11 01 2015 06 16 0140-6736 2 8405 1984 Sep 29 Lancet (London, England) Lancet Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients. 707-11 127 patients with suspected herpes simplex encephalitis (HSE) were entered in a prospective randomised study of acyclovir 10 mg/kg 8-hourly versus (...) vidarabine 15 mg/kg daily for 10 days. The patients were consecutive and nearly all Swedish cases of HSE were included; they were treated in six university infectious diseases departments. The diagnosis of HSE was verified by brain biopsy and/or antibody responses in serum and cerebrospinal fluid. Of 53 confirmed cases of HSE (corresponding to 2 X 3 cases per million inhabitants per year in Sweden), 51 (27 acyclovir, 24 vidarabine) were evaluable for analysis of efficacy. The mortality was 19

Lancet1984

59. Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection.

Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection. 6088819 1984 10 16 1984 10 16 2016 10 17 0098-7484 252 9 1984 Sep 07 JAMA JAMA Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection. 1147-51 One hundred nineteen patients with primary and 31 patients with nonprimary first-episode genital herpes were treated for ten days with 200 mg of acyclovir capsules or placebo capsules (...) orally five times daily. Among acyclovir recipients with primary genital herpes, the median duration of viral shedding (two days), time to crusting of all lesions (seven days), time to healing of all lesions (12 days), and duration of local pain (five days) and constitutional symptoms (three days) were shorter than among placebo recipients (9, 10, 16, 7, and 6 days, respectively). Among patients with nonprimary first-episode genital herpes, oral acyclovir shortened the median duration of viral

JAMA1984

60. Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir.

Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir. 6328297 1984 07 09 1984 07 09 2013 11 21 0028-4793 310 24 1984 Jun 14 The New England journal of medicine N. Engl. J. Med. Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir. 1545-50 We studied 35 otherwise healthy adults with frequently recurring genital herpes (greater than or equal to 1 episode per month), in a double-blind (...) trial comparing oral acyclovir with placebo capsules for suppression of recurrent infection. The patients were treated for 125 days unless herpes recurred. Among 32 evaluable patients, there were significantly fewer recurrences during acyclovir treatment (4 of 16) than during placebo treatment (16 of 16, P less than 0.001). The mean duration of therapy was significantly longer for patients receiving acyclovir than for those receiving placebo (114.9 vs. 24.8 days, P less than 0.001). Of 19 patients

NEJM1984